The obesity paradox in metastatic castration-resistant prostate cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The obesity paradox in metastatic castration-resistant prostate cancer
Authors
Keywords
-
Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-05
DOI
10.1038/s41391-021-00418-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data
- (2021) Alberto Martini et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index
- (2020) Christine Desmedt et al. JOURNAL OF CLINICAL ONCOLOGY
- The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
- (2019) Douglas Donnelly et al. Journal for ImmunoTherapy of Cancer
- Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database
- (2018) Adriana C. Vidal et al. BJU INTERNATIONAL
- Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer
- (2018) Jong Soo Lee et al. JOURNAL OF UROLOGY
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
- (2018) Jennifer L McQuade et al. LANCET ONCOLOGY
- Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
- (2018) Ziming Wang et al. NATURE MEDICINE
- Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity — United States, 2005–2014
- (2017) C. Brooke Steele et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations
- (2016) Laurence Albiges et al. JOURNAL OF CLINICAL ONCOLOGY
- Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database
- (2016) A C Vidal et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
- (2015) Daniel P Petrylak et al. LANCET ONCOLOGY
- Association of Body Composition with Outcome of Docetaxel Chemotherapy in Metastatic Prostate Cancer: A Retrospective Review
- (2015) Weixin Wu et al. PLoS One
- The obesity paradox: Understanding the effect of obesity on mortality among individuals with cardiovascular disease
- (2014) Hailey R. Banack et al. PREVENTIVE MEDICINE
- The “Obesity Paradox” Explained
- (2013) Hailey R. Banack et al. EPIDEMIOLOGY
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
- (2013) Ian F Tannock et al. LANCET ONCOLOGY
- Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers
- (2012) Anne E. Utech et al. Journal of Cachexia Sarcopenia and Muscle
- Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
- (2011) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival
- (2010) Paul L. Nguyen et al. JOURNAL OF CLINICAL ONCOLOGY
- The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer
- (2008) A J Armstrong et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Obesity Is a Significant Risk Factor for Prostate Cancer at the Time of Biopsy
- (2008) Stephen J. Freedland et al. UROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now